Copyright
©The Author(s) 2024.
World J Gastrointest Oncol. Apr 15, 2024; 16(4): 1236-1247
Published online Apr 15, 2024. doi: 10.4251/wjgo.v16.i4.1236
Published online Apr 15, 2024. doi: 10.4251/wjgo.v16.i4.1236
Variables | Total (n = 102) |
Best overall response | |
CR | 10 |
PR | 53 |
SD | 20 |
PD | 19 |
Objective response rate | 61.76% |
Disease control rate | 81.37% |
Median PFS | 10.07 months (95%CI: 8.50-11.65) |
6-month tumor PFS | 70.82% (95%CI: 60.80-78.72) |
12-month tumor PFS | 36.11% (95%CI: 26.49-45.79) |
Median OS | 26.43 months (95%CI: 17.00-35.87) |
6-month survival | 92.63% (95%CI: 85.14-96.42) |
12-month survival | 84.15% (95%CI: 74.05-90.56) |
- Citation: Ma KP, Fu JX, Duan F, Wang MQ. Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma. World J Gastrointest Oncol 2024; 16(4): 1236-1247
- URL: https://www.wjgnet.com/1948-5204/full/v16/i4/1236.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v16.i4.1236